Vericel/$VCEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vericel
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
- Ticker
- $VCEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 398
- Headquarters
- Burlington, United States
- Website
- www.vcel.com
Vericel Metrics
BasicAdvanced
$2.9B
93.25
$0.62
1.06
-
Price and volume
Market cap
$2.9B
Beta
1.06
52-week high
$59.75
52-week low
$28.95
Average daily volume
817K
Financial strength
Current ratio
5.131
Quick ratio
4.607
Long term debt to equity
0.199
Total debt to equity
0.236
Interest coverage (TTM)
42.01%
Profitability
EBITDA (TTM)
40.573
Gross margin (TTM)
74.47%
Net profit margin (TTM)
10.27%
Operating margin (TTM)
8.32%
Effective tax rate (TTM)
2.51%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
3.47%
Return on equity (TTM)
9.44%
Valuation
Price to earnings (TTM)
93.247
Price to revenue (TTM)
9.033
Price to book
7.64
Price to tangible book (TTM)
7.75
Price to free cash flow (TTM)
50.58
Free cash flow yield (TTM)
1.98%
Free cash flow per share (TTM)
1.137
Growth
Revenue change (TTM)
25.30%
Earnings per share change (TTM)
150.13%
3-year revenue growth (CAGR)
20.51%
10-year revenue growth (CAGR)
19.79%
3-year earnings per share growth (CAGR)
41.87%
10-year earnings per share growth (CAGR)
-5.78%
What the Analysts think about Vericel
Analyst ratings (Buy, Hold, Sell) for Vericel stock.
Analyst projections of the future price of Vericel stock.
Bulls say / Bears say
MACI remains a strong growth engine: third-quarter sales rose 21%, its sixth straight quarter of growth above 20%, with record biopsies and implants. Vericel raised its full-year MACI revenue outlook to $290–292 million. (GlobeNewswire)
The burn-care franchise is growing quickly too: revenue rose 52% to a record $18 million, while commercial NexoBrid sales increased 54% and Epicel sales rose 23%. Repeat orders from about 70 of the more than 80 centres that have ordered NexoBrid point to wider use. (GlobeNewswire, The Motley Fool)
Profitability and cash generation are improving: third-quarter net income rose 179%, adjusted EBITDA margin reached 30%, and free cash flow was $15.7 million. Vericel raised its full-year adjusted EBITDA margin outlook to 28% and ended the quarter with $235.6 million in cash and investments and no debt. (GlobeNewswire)
Revenue is concentrated in MACI: it generated about 79% of third-quarter sales. A slowdown in surgeon adoption or pressure on reimbursement could therefore weigh heavily on results. (GlobeNewswire, SEC)
Burn-care demand can be difficult to forecast: management said it cannot control how many catastrophic burns occur or how many patients survive to be treated. That makes Epicel sales, and quarterly results, less predictable. (The Motley Fool)
Manufacturing and supply disruptions could limit growth: Vericel is transitioning MACI production to its Burlington facility and warns that scaling its own manufacturing or securing NexoBrid supplies from MediWound could be difficult. The company also flags potential disruption to supply and shipping routes in the Middle East. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Vericel Financial Performance
Revenues and expenses
Vericel Earnings Performance
Company profitability
Upcoming events
No upcoming events
Vericel News
AllArticlesVideos
Funds containing Vericel
Fund name | Fund size | $VCEL weighting |
|---|---|---|
iShares Ageing Population£AGES | $887M | 0.27% |
iShares Ageing Population$AGED | $887M | 0.27% |
iShares Ageing Population€AGED | $887M | 0.27% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.20% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
